News

Alamar Biosciences and Nightingale Health have partnered with the UK Biobank to launch a study to identify early blood biomarkers for neurodegenerative conditions such as Parkinson’s disease. Called UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, the study will measure hundreds of…

Physiotherapy using augmented reality (AR) glasses may offer a feasible, safe, and user-friendly way for people with Parkinson’s disease to practice walking and balance exercises at home, a study found. The approach combines physical exercise with interactive digital games, allowing people to train at home while therapists remotely prescribe and…

WellPD, an approved wrist-worn device that allows people with Parkinson’s disease to monitor both their symptoms and treatment responses at home, is now available for purchase in the U.S. and other countries, including the U.K. and Australia. Its U.S.-based developer,…

People with Parkinson’s disease have different bacteria in their gut, the predicted functions of which differ from those in healthy people, according to a study from southern India that adds further evidence for a possible link between the gut, inflammation, and the disease. “These findings identify candidate microbial signatures and…

An extract from the seeds of Mucuna monosperma, a flowering plant, protected nerve cells in the brain and restored dopamine in a rat model of Parkinson’s disease, a study has found. However, more research is needed to determine whether it is safe and effective for patients. Dopamine is a…

Variations in gut bacteria do not appear to substantially affect motor symptom severity in Parkinson’s disease, but they may be linked to cognitive issues in Parkinson’s, according to a new study. “Gut-derived features, including both [gut bacteria themselves and the molecules that are made by gut bacteria], are more…

Vertero Therapeutics has completed patient enrollment in a Phase 1b clinical trial testing VT-5006, an experimental treatment designed to target gut-related mechanisms believed to contribute to Parkinson’s disease. The Phase 1b study (NCT07310264) includes 24 adults with early- or moderate-stage Parkinson’s. It will assess the treatment’s safety…

A clinical trial designed to identify more effective resistance-training strategies to improve muscle strength, power, and the ability to perform everyday activities in people with Parkinson’s disease is recruiting patients with mild to moderate symptoms at the University of Miami in Florida. The study (NCT07840508), dubbed “Comparison of…

An artificial intelligence model that analyzes routine checkup data and blood fat levels may help doctors spot which people with Parkinson’s disease are at higher risk for future memory and thinking problems. By flagging at-risk individuals early, this approach could one day help doctors and families plan ahead long…

In a small proof-of-concept clinical trial, Biovie’s experimental oral therapy bezisterim was associated with significantly greater improvements in motor and nonmotor symptom scores than a placebo among people with early-stage Parkinson’s disease who had higher levels of a potential inflammation marker. The findings come from an exploratory subgroup analysis.